Should Assessing T-Cell Response Be an Essential Part of COVID-19 Vaccine Development?

October 1, 2020

Discussions on COVID-19 immune responses, including the responses in early vaccine clinical studies, have focused largely on antibody responses.

However, recent data indicate that the cellular immune response also plays an important role and should be considered when evaluating the immune response.

Assessing T-cell responses can provide critical information about vaccine responses and the development and persistence of protective immunity against SARS-CoV-2 that will be critical in the fight against COVID-19.

CLICK HERE TO VIEW THE WEBINAR

The webinar is co-sponsored by Caprion-HistoGeneX  and WCG and will feature the following speakers:

Scott Gottlieb, M.D., Former Commissioner of the Food and Drug Administration (FDA)
Dr. Gottlieb will discuss the implications of immune response testing for overall assessment, regulatory approval, and public acceptance of COVID-19 vaccines.

James Rothman, Ph.D., Sterling Professor of Cell Biology, Yale University; Recipient, Nobel Prize in Medicine, 2013
Dr. Rothman will provide an overview of the immune response to SARS-CoV-2 and the importance of cellular immunity. The key findings from our previous experiences with SARS-CoV-1 as well as the latest publications will also be discussed.

Eustache Paramithiotis, Ph.D., Vice President, Research & Development, Caprion-HistoGeneX
Testing methods for understanding complex immune system reactions as part of vaccine development programs will be discussed by Dr. Paramithiotis. Information on the methodology and accuracy of these assays will be provided.

Our speakers will discuss:

• An overview of the current state of COVID-19 vaccine development
• The adaptive immune response to SARS-CoV-2 and the importance of cellular immunity

• Testing methods and assay standardization for understanding complex immune system reactions as part of vaccine development programs

Learn more about CellCarta